Veru Inc VERU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.77
- Day Range
- $2.72–2.81
- 52-Week Range
- $2.07–7.30
- Bid/Ask
- $2.77 / $2.79
- Shares Outstanding
- 17.05M
- Market Cap
- $43.98M
- Volume/Avg
- 38,576 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.verupharma.com
Valuation
|
Metric
|
VERU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
VERU
Financial Strength
|
Metric
|
VERU
|
|---|---|
Quick Ratio | 4.19 |
Current Ratio | 4.42 |
Interest Coverage | — |
Quick Ratio
VERU
Profitability
|
Metric
|
VERU
|
|---|---|
Return on Assets (Normalized) | −65.86% |
Return on Equity (Normalized) | −90.87% |
Return on Invested Capital (Normalized) | −81.79% |
Return on Assets
VERU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zF!j%xM | LOCK|M>t^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n^Hd^xv | LOCK|sk!Qv | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#fzFb^ | LOCK|gc | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Vq#rqr? | LOCK|mPqS@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#tG@&X | LOCK|$y | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|sgCN%MD | LOCK|V?d& | $29B | |||
| Incyte Corp
INCY
| LOCK|!@LxB#n | LOCK|G^ | $25B | |||
| Moderna Inc
MRNA
| LOCK|>>^>prP | LOCK|!g@ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|TyYg?B% | LOCK|sX | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%!>G<kh | LOCK|l< | $17B |
United States